LOS ANGELES, CA--(Marketwire - Mar 20, 2012) - Dr. Ramin "Ron" Najafi founded NovaBay Pharmaceuticals, Inc. (NYSE Amex: [ NBY ]) and has guided it to become a truly unique specialty pharmaceutical company focused on developing what he calls "a non-antibiotic technology" which is based on white blood cell active compounds. These anti-infective compounds are designed to treat and prevent a number of antibiotic-resistant infections.

These proprietary Aganocide compounds are developed to treat and prevent a wide range of infections without causing bacterial resistance. The company has several internal development programs including Phase II clinical level studies in Ophthalmology, Dermatology and Urology. In wound care, the firm is ready to commercialize and distribute product across the United States and beyond.

Dr. Najafi, who in his time at NovaBay served in various management positions -- including as Chief Scientific Officer -- is clearly excited about the firm's prospects.

"It's going to be a very exciting year for NovaBay," explains Najafi. "We'll be announcing data, clinical trial news and we also anticipate announcing additional partnerships. I think 2012 will be a phenomenal year for the company."

Shares of the firm took off last December after Najafi first told BioMedReport's readers about [ "A Potent and Safe Wound Care Agent" ] during an Expert Briefing which he authored. In it, he described some of the problems facing medical practitioners dealing with chronic non-healing wounds, such as venous stasis ulcers, diabetic ulcers, and pressure ulcers -- all of which are serious unmet medical needs that effect a patient's morbidity and mortality.

Now, in an exclusive video interview, Dr. Najafi explains some of the firm's upcoming milestones and key developments.

With so many catalysts and forward looking developments, it's easy to understand why speculators and investors have been bringing volume and attention to the stock.

The video interview with Dr. Najafi is now available at:
[ http://www.biomedreports.com/2012032091586/novabay-set-for-phenomenal-year-with-key-upcoming-clinical-data-announcements-and-partnership-developments.html ]

In addition, investors interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades during these volatile markets can go to:
[ http://biomedreports.com/fdacal.html ]

News developments and live healthcare sector updates are available constantly via Twitter at: [ http://twitter.com/BioMedReports ]

About BioMedReports.Com

BioMedReports is a news portal covering the biomedical news and financial sector. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies in the healthcare sector of the markets. Full disclosures and information about these stocks and news are available at BioMedReports.Com